Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

计划入组 20 人 · 首次发布于 2021 年 8 月 6 日

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

计划入组 59 人 · 首次发布于 2020 年 12 月 16 日

Safety Study of SGN-CD70A in Cancer Patients

计划入组 38 人 · 首次发布于 2014 年 8 月 15 日

SGN-CD70A

CD79b CAR-T Cells

CD79-targeted immunotoxins (Genentech)

Simcere Zaiming Licenses Tri-Specific Antibody SIM0660 to Roche in Deal Worth Up to $1.53 Billion

GSK Pays Up to $750M for Chimagen Trispecific T-Cell Engager in Multiple Myeloma